/
IGC
$0.27+$0.01 (+3.04%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$26.3M
100M shares
52-week range
$0.24 – $0.50
11% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
XASE
CS
Borrow rate
0.61%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-1.45
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.1M | $4.1M | $898.0K | $397.0K | $911.0K | $1.3M | $1.3M | $1.2M |
| Cost of revenue | $5.0M | $4.0M | $1.2M | $203.0K | $1.1M | $612.0K | $652.0K | $834.0K |
| Gross profit | $132.0K | $115.0K | −$349.0K | $194.0K | −$158.0K | $733.0K | $619.0K | $352.0K |
| Gross margin | 2.6% | 2.8% | -38.9% | 48.9% | -17.3% | 54.5% | 48.7% | 29.7% |
| R&D | $1.3M | $1.0M | $929.0K | $2.3M | $3.5M | $3.8M | $3.7M | $5.2M |
| Operating income | −$4.6M | −$6.9M | −$8.7M | −$15.4M | −$11.6M | −$9.8M | −$7.4M | −$10.2M |
| EBITDA | −$4.6M | −$6.7M | −$8.3M | −$14.4M | −$10.8M | −$12.4M | −$6.7M | −$6.2M |
| Net income | −$4.1M | −$7.3M | −$8.8M | −$15.0M | −$11.5M | −$13.0M | −$7.1M | −$6.5M |
| Net margin | -80.1% | -179.6% | -981.2% | -3782.4% | -1263.0% | -966.5% | -560.3% | -552.1% |
| EPS (diluted) | -0.12 | -0.19 | -0.21 | -0.30 | -0.22 | -0.22 | -0.09 | -0.07 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2027 | $857000 | $-0.09 | $-0.09–$-0.09 | 1 |
| 2028 | $857000 | $-0.08 | $-0.08–$-0.08 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
IGC Pharma, Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
www.igcinc.us- Employees
- 70
- IPO / List date
- Apr 13, 2006
- HQ
- POTOMAC, MD
Held by traders on TradeandTell
No one on the platform currently holds IGC.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 483,975 | $127.3K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2013-04-19 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded IGC yet.
